A multicenter, randomized, double-blinded, parallel-design study to evaluate the lipid-altering efficacy of 2 formulations of MK0524A [niacin/laropiprant] compared to Niaspan (TM) [niacin]

Trial Profile

A multicenter, randomized, double-blinded, parallel-design study to evaluate the lipid-altering efficacy of 2 formulations of MK0524A [niacin/laropiprant] compared to Niaspan (TM) [niacin]

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Feb 2016

At a glance

  • Drugs Niacin/laropiprant (Primary) ; Niacin
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 06 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top